论文部分内容阅读
目的研究亚胺培南/西司他丁治疗院内获得性重症肺炎的疗效及安全性,为临床经验性用药提供参考。方法亚胺培南/西司他丁治疗院内获得性重症肺炎共93例,剂量为亚胺培南/西司他丁0.5~1.0 g静脉滴注,每8 h或12 h一次,疗程7~10 d。观察临床症状及不良反应,并对患者的痰液进行培养及药敏试验。结果亚胺培南/西司他丁治疗院内获得性重症肺炎的临床有效率为78.4%(73/93),细菌清除率为89.1%(74/83),不良反应率为5.3%(5/93)。结论亚胺培南/西司他丁治疗院内获得性重症肺炎的疗效确切、安全性好,但应密切监测细菌耐药性的变化,根据病原学及临床效果及时调整治疗方案。
Objective To study the efficacy and safety of imipenem / cilastatin in the treatment of nosocomial severe pneumonia and provide a reference for clinical experience. Methods The imipenem / cilastatin treatment of nosocomial severe pneumonia in 93 cases, the dose of imipenem / cilastatin 0.5 ~ 1.0 g intravenously, every 8 h or 12 h, a course of 7 ~ 10 d. Observation of clinical symptoms and adverse reactions, sputum and patient susceptibility testing. Results The clinical efficacy of imipenem / cilastatin in hospital-acquired severe pneumonia was 78.4% (73/93), the bacterial clearance rate was 89.1% (74/83) and the adverse reaction rate was 5.3% (5 / 93). Conclusion The efficacy of imipenem / cilastatin in hospital-acquired severe pneumonia is good and safe. However, the change of bacterial resistance should be closely monitored. The treatment regimen should be timely adjusted according to the etiology and clinical effect.